Author

D. Rossi

Institutions: Institute of Oncology Research, Istituto Oncologico della Svizzera Italiana, Università della Svizzera italiana

Observed institutions: Institute of Oncology Research, Istituto Oncologico della Svizzera Italiana, Università della Svizzera italiana

OpenAlex ID: A5043448176

Metabolic heterogeneity‐based radiomic model predicts treatment outcomes of primary mediastinal B‐cell lymphoma patients in the IELSG37 study

2026 · L. Ceriani, L. Milan, et al. · British Journal of Haematology

P646: Effectiveness and Safety of Venetoclax in Combination With Rituximab (venr) in R/r Cll Patients With or Without Risk-associated Genetic Markers – Data From the Observational Verve Study

2022 · I. Schwaner, H. Hebart, et al. · HemaSphere

P1282: Disease-specific U1 Spliceosomal Rna Mutations in Mature B-cell Neoplasms

2022 · F. Nadeu, S. Shuai, et al. · HemaSphere

Works count: 3

Citation count:

H-index:

I10-index: